Innovative Drug Discovery
We are pursuing the development of new biologics, natural pharmaceutical products and small-molecule drugs through our Protein REFolding enhancER (PREFER) technology, recombinant protein mass production technology, monoclonal antibody screening technology, cell culture technology, and biological efficacy assessment technology.
In particular, we are able to effectively screen and discover drug candidates for biomarker-based targeted therapy, evaluate efficacy, select patient groups for clinical studies, monitor efficacy, and assess effectiveness through our core strengths including the discovery, analysis, and evaluation of biomarkers. We aim to integrate the development of innovative new drugs and the companion diagnostics (CDx) to enable personalized management.
We also intend to strengthen our new drug portfolio through active Connect & Development (C&D). We will continue to dedicate ourselves for exploration, discovery, validation, and development of innovative new drug candidates.